|Bid||86.10 x 800|
|Ask||88.69 x 1000|
|Day's Range||84.01 - 86.79|
|52 Week Range||53.06 - 123.99|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
In a note out Thursday, Stifel analyst Daniel Arias wrote that the company was “set up to deliver” in 2020, and that with shares down significantly in recent months, it’s a good time to buy Exact Sciences (ticker: EXAS). As of Thursday’s close, shares of Exact Sciences were up 25.6% so far this year, but down 33% over the past three months. The stock fell sharply in early September on news of a study that raised questions about the effectiveness of Cologuard, the company’s home fecal screen for colon cancer.
Exact Sciences Corporation (NASDAQ:EXAS) shareholders might be concerned after seeing the share price drop 29% in the...
Genomic Health chairman and CEO Kim Popovits is leaving the company as part of the combination of the two companies.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 29) Cabaletta Bio Inc (NASDAQ: CABA ) Edwards Lifesciences ...
Exact Sciences (EXAS) delivered earnings and revenue surprises of 24.39% and 1.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Chairman and CEO Kim Popovits has been in various leadership positions with the Redwood City company since 2002.
Third-quarter test volume for Cologuard is up to 456,000 completed tests, an increase of 89% compared with the same quarter in 2018.
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
Kevin Conroy became the CEO of Exact Sciences Corporation (NASDAQ:EXAS) in 2009. First, this article will compare CEO...
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
In the weeks leading up to unveiling a $2.8 billion cash-and-stock merger — and especially in the final few days — top executives and directors of Genomic Health Inc. were locked in a fierce back-and-forth with Exact Sciences Corp. that at one point led the pioneering Redwood City-based cancer test maker to reject the deal. In a Securities and Exchange Commission filing late Friday ahead of a Nov. 7 shareholder vote on the deal, Genomic Health (NASDAQ: GHDX) said its board rejected Madison, Wisconsin-based Exact Sciences' (NASDAQ: EXAS) offer before ultimately agreeing to a $72-per-share price. Midway through negotiations, a financial adviser reached out to Genomic Health on behalf of an "unnamed strategic player" based outside the United States that was in the early stages of considering delving into the U.S. health care market via a transaction.
Nearly 3 million people have been screened for colorectal cancer with the company’s DNA-based Cologuard take-home test since the U.S. Food and Drug Administration approved it in 2014. Half of those that were tested were previously unscreened.